Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of Dasatinib Plus Gemcitabine in Locally-advanced Pancreatic Cancer
2010-024595-26Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- May 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing Gemcitabine + Dasatinib with Gemcitabine + Placebo (2 arms). Primary endpoint: Overall survival. Started May 2011; status: completed.
02
Drugs
dasatinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2010-024595-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024595-26.